Sarepta Therapeutics’ Target Raised and 4 Stock Analyses Making the Rounds
Zillow Inc. (NASDAQ:Z): ThinkEquity believes that concerns over the mix shift and pricing of Zillow Inc.’s Premier Agent offerings are short-term issues. After meeting with the company’s management,...
View ArticleAT&T Jumps on Clean Energy Bandwagon and 4 Hot Stocks Moving Today
Facebook, Inc. (NASDAQ:FB) informed ad marketers that it is effective for advertising due to the fact that it knows who its users are and whom they trust, The New York Times reports. Facebook allows...
View ArticleHealthcare Business Update: Bristol-Myers Returns Rights, Sarepta Shares In...
Bristol-Myers Squibb Company (NYSE:BMY) is returning its share of overseas rights to the blood thinner Plavix and blood pressure treatment Avalide to Sanofi-Aventis (NYSE:SNY) subsequent to the loss of...
View ArticleLin TV Expands in NYC and 3 Stocks that Have Hit 52-Week Highs
Sirius Xm Radio Inc. (NASDAQ:SIRI): The FCC has asked for public comment regardubg Liberty Media Corp.’s (NASDAQ:LINTA) application to be approved to take control of Sirius XM Radio, indicating that...
View ArticleMcKesson Renewal Deemed Positive and 4 Stock Analyses to Track
McKesson Corporation (NYSE:MCK) contract renewal with Rite Aid (NYSE:RAD) is seen as a positive by UBS, and it is far ahead of its April 2013 expiration. The analyst stated the renewal should remove...
View ArticleH-P’s Strategy Still Unclear and 4 Stock Analyses Making the Rounds
Eli Lilly and Company’s (NYSE:LLY) projected Monday release of Solaezumab causes Credit Suisse to foresee positive risk and reward. Downside risk is calculated at 5 percent with the upside potential at...
View ArticleHere’s a New Treatment for Muscular Dystrophy
In a statement released Wednesday, Sarepta Therapeutics (NASDAQ:SRPT) said its new treatment for Duchenne muscular dystrophy helped patients walk farther, pushing the company’s stock price up 165...
View ArticleClik here to view.
Here are 5 Biopharmaceutical Companies on the Rise
There are numerous bio-pharmaceutical companies developing potential groundbreaking treatments, and even cures, for diseases like Duchenne muscular dystrophy and rare types of Leukemia. Market...
View ArticleApple Analyst Sees $760 Ahead and 3 Stock Insights to Eye
Joy Global, Inc (NYSE:JOY) risk/reward is seen by Barclays as being favorable, especially when considering solid earnings visibility and possible aftermarket growth. Shares have an Overweight rating...
View ArticleHealthcare Business Update: Sarepta Presents Data, Pharmacyclics Enrolls 5th...
Sarepta Therapeutics (SRPT) presented phase IIb data over the weekend indicating that its eteplirsen treatment for Duchenne Muscular Dystrophy is effective. Piper Jaffray believe that the medication...
View Article
